Abbott Expects RA Agent D2E7 To Capture 25% Of Market, Touts Production

Abbott predicts it has existing production capacity for its rheumatoid arthritis treatment D2E7 (adalimumab) to serve the market up to five years, even at ambitious growth projections.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet